• PDG106 EFFECTS OF STATIN THERAPY ON LONG-TERM HEALTH CARE OUTCOMES AND MEDICAL COST-BASED ON CHINA REGIONAL HEALTH INSURANCE CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PCV58 TOTAL COSTS OF TREATMENT OF PATIENTS SUFFERING FROM VENOUS THROMBOEMBOLISM - IMPLICATIONS OF DIFFERENT COST PERSPECTIVES

    Nov 1, 2019, 00:00

  • PCN202 LIQUID BIOPSY FOR EGFR+ PATIENTS IN ADVANCED NSCLC: THE IMPACT OF DIFFERENT STRATEGIES

    Nov 1, 2019, 00:00

  • PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY

    Nov 1, 2019, 00:00

  • RARE Statistical Research

    Nov 1, 2019, 00:00

  • PBI55 FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US

    Nov 1, 2019, 00:00

  • SP3 PATIENTS' PREFERENCES FOR BREAST CANCER TREATMENTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY FROM SPAIN, FRANCE, POLAND AND IRELAND

    Nov 1, 2019, 00:00

  • PCN315 USE OF NOVEL HORMONAL AGENTS IN THE MONTH BEFORE DYING IN MEN DYING OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PMU37 NEWLY DIAGNOSED NONALCOHOLIC FATTY LIVER DISEASE AFTER BARIATRIC SURGERY: A STUDY OF ELECTRONIC MEDICAL RECORD DATA

    Nov 1, 2019, 00:00

  • PDB107 A COMPARISON BETWEEN THE EQ-5D-5L AND THE SF-6D IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • PDG29 ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION

    Nov 1, 2019, 00:00

  • Medical Devices - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN86 HEALTHCARE RESOURCE UTILIZATION FOR CETUXIMAB + CHEMOTHERAPY ADMINISTERED EVERY OTHER WEEK VS ONCE WEEKLY FOR TREATMENT OF METASTATIC COLORECTAL CANCER: REAL-WORLD OUTCOMES FROM A US CLAIMS DATABASE STUDY

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PMU5 ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS WITH HEPATIC DISEASES AT THE DEPARTMENT OF GASTROENTEROLOGY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PMH23 A RETROSPECTIVE CHART REVIEW STUDY TO QUANTIFY THE MONTHLY MEDICAL RESOURCE USE AND COSTS OF TREATING PATIENTS WITH TREATMENT RESISTANT DEPRESSION IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS259 NATIONAL HTA IMPLEMENTATION IN MIDDLE-INCOME COUNTRIES, THE CASE OF JORDAN

    Nov 1, 2019, 00:00

  • PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 ...

    Nov 1, 2019, 00:00

  • PCN104 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES OF CANCER IMMUNOTHERAPY MEDICINES

    Nov 1, 2019, 00:00

  • PND70 NARCOLEPSY TREATMENT IN SWEDEN: REGISTER BASED STUDY

    Nov 1, 2019, 00:00

  • PNS179 HOW DOES EXTERNAL REFERENCE PRICING FOR MEDICARE PART B DRUGS COMPARE TO OTHER COST METRICS AVAILABLE IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PRO131 WHAT DO WE KNOW ABOUT PATIENT'S AND CAREGIVERS' EXPERIENCE WHEN LIVING WITH THE HEREDITARY RETINAL CONDITION RETINITIS PIGMENTOSA?

    Nov 1, 2019, 00:00

  • PCV60 BURDEN OF CARDIOVASCULAR DISEASE AND POTENTIAL IMPACT OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PIT9 IMPACT OF FALLS IN THE ELDERLY POPULATION FOR THE SPANISH NATIONAL HEALTH SYSTEM

    Nov 1, 2019, 00:00

  • PCV101 REAL-WORLD COST AND EFFECTIVENESS ANALYSIS OF POST-ACUTE CARE VS. NON-PAC FOR STROKE PATIENTS AFTER DISCHARGE FROM HOSPITAL

    Nov 1, 2019, 00:00

  • PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PNS4 A REVIEW OF PERFOS IN FDA AND EMA LABELLING CLAIMS (2009-2019)

    Nov 1, 2019, 00:00

  • Drugs Statistical Research

    Nov 1, 2019, 00:00

  • PRO121 THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT OF MEDICATIONS FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • PRO41 COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.

    Nov 1, 2019, 00:00

  • PDG49 THE IMPACT OF FUTURE MEDICAL COSTS ON DUTCH PHARMACOECONOMIC ASSESSMENTS

    Nov 1, 2019, 00:00

  • PDG73 INCLUSION OF ADVERSE EVENTS IN THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: A REVIEW OF THE MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Nov 1, 2019, 00:00

  • PSU41 COMPLIANCE WITH SURGICAL ANTIBIOTIC PROPHYLAXIS FOR OBSTETRIC AND GYNECOLOGIC SURGERIES IN NIGERIA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PCV91 CHANGES IN THE MORTALITY RELATED TO ISCHAEMIC HEART DISEASE IN PEOPLE ABOVE 65 YEARS BETWEEN 1990-2015 IN WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • Injury Trauma - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS135 ARE THE SALES FORECAST FOR MEDICAL DEVICES ACCURATE? A RETROSPECTIVE ANALYSIS IN FRANCE (2018-2019)

    Nov 1, 2019, 00:00

  • PMU9 HIGH DRUG PRICES AND THE ADEQUACY OF RETURN ON PUBLIC INVESTMENT INTO DRUG RESEARCH AND DEVELOPMENT BY THE U.S. NATIONAL INSTITUTES OF HEALTH (NIH).

    Nov 1, 2019, 00:00

  • PCN473 PREFERENCES FOR CHEMOTHERAPY SIDE EFFECTS IN SAUDI BREAST CANCER PATIENTS: A DISCRETE-CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • PDG37 REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE)

    Nov 1, 2019, 00:00

  • PDB111 EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PND92 TREATMENT PATTERNS AND CHARACTERIZATION OF MIGRAINE PATIENTS FOLLOWED IN HEADACHE SPECIALIZED CENTERS OF PORTUGAL

    Nov 1, 2019, 00:00

  • PIN85 POTENTIAL PUBLIC HEALTH IMPACT OF REACHING THE WHO/EU TARGET OF 75% INFLUENZA VACCINATION COVERAGE AMONG THE ELDERLY IN GERMANY

    Nov 1, 2019, 00:00

  • PCN98 COST-COMPARISON ANALYSIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) AND TRANSARTERIAL CHEMOEMBOLISATION (TACE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • NO Specific Disease - Medical Technologies

    Nov 1, 2019, 00:00

  • PNS267 MODELLING OF LIFECYCLE PRICING IN HTA: METHODOLOGICAL CONSIDERATIONS

    Nov 1, 2019, 00:00

  • PBI57 PAYER AND PHYSICIAN DYNAMICS SURROUNDING BIOSIMILAR ACCESS IN THE EU

    Nov 1, 2019, 00:00

  • PCN204 COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+ BREAST CANCER IN AN INSTITUTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PRS15 COMPARISON OF HOSPITALIZATION RATES AND LIMITATION OF DAILY ACTIVITIES IN SEVERE ASTHMA PATIENTS RECEIVING BIOLOGIC AND NON-BIOLOGIC TREATMENT REGIMENS

    Nov 1, 2019, 00:00

  • PMU149 DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CANCER PATIENTS: DID THEY INCREASE IN RECENT YEARS?

    Nov 1, 2019, 00:00

  • PMH24 DEPENDENCE AS A MEASURE OF HEALTH BENEFIT IN THE ECONOMIC EVALUATION OF DEMENTIA INTERVENTIONS

    Nov 1, 2019, 00:00

  • PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

    Nov 1, 2019, 00:00

  • PND52 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PRS24 COST EFFECTIVENESS OF BENRALIZUMAB FOR SEVERE, UNCONTROLLED ORAL CORTICOSTEROID-DEPENDENT ASTHMA IN SWEDEDN

    Nov 1, 2019, 00:00

  • PNS183 UNIVERSAL HEALTH INSURANCE COVERAGE FOR CHILDREN UNDER AGE 6: FACTORS ASSOCIATED WITH THE USE OF PRIVATE OVER PUBLIC HEALTH SERVICES IN VIETNAM

    Nov 1, 2019, 00:00

  • PNS19 THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE'S HIGHLY SPECIALISED TECHNOLOGIES PROCESS: A REVIEW OF PAST SUBMISSIONS AND RECOMMENDATIONS FOR THE FUTURE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PNS243 TRENDS IN DECISIONS BY THE SCOTTISH MEDICINES CONSORTIUM OVER THE PAST 10 YEARS - AN ANALYSIS OF KEY FACTORS DRIVING ACCEPTANCE

    Nov 1, 2019, 00:00

  • PMS55 TREATMENT PATTERNS AMONG MS PATIENTS NEWLY INITIATING DISEASE-MODIFYING THERAPY

    Nov 1, 2019, 00:00

  • Injury Trauma - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PRS29 COMPARATIVE PHARMACOECONOMICS OF BX IN THE TREATMENT OF PATIENTS WITH UNCONTROLLED MODERATE AND SEVERE ATOPIC ASTHMA IN THE RUSSIAN HEALTH CARE SETTING

    Nov 1, 2019, 00:00

  • MT2 UNDERSTANDING POTENTIAL CAPACITY CONSTRAINTS RESTRICTING TIME-TO-DIAGNOSIS IN A MULTI-DISCIPLINARY DIAGNOSTIC CENTRE (MDC) FOR PEOPLE WITH NON-SPECIFIC SYMPTOMS OF CANCER: A DISCRETE EVENT SIMULATION

    Nov 1, 2019, 00:00

  • PNS394 DEVELOPMENT OF A MULTIPLICATIVE MULTI-ATTRIBUTE AND SINGLE-ATTRIBUTE UTILITY FUNCTION FOR THE HUI3 IN JAPAN

    Nov 1, 2019, 00:00

  • PIN135 MODELING HUMAN PAPILLOMAVIRUS TRANSMISSION FOR VACCINE EVALUATIONS: A PRELIMINARY AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PMU97 A REVIEW OF CONTRIBUTIONS MADE BY PATIENT ADVOCACY GROUPS IN THE ASSESSMENT OF DRUGS BY THE FRENCH HAUTE AUTORITE DE SANTE

    Nov 1, 2019, 00:00

  • Neurological Disorders Studies

    Nov 1, 2019, 00:00

  • PRS30 PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION+ VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PGI18 ASSESSMENT OF MEDICAL COSTS ASSOCIATED WITH CROHN'S DISEASE: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS246 EMA G-BA - A COMPARISON OF TIME LIMITATIONS OF EUROPEAN MARKETING AUTHORIZATIONS AND GERMAN ADDED BENEFIT ASSESSMENTS FOR NEW PHARMACEUTICALS.

    Nov 1, 2019, 00:00

  • PCN291 ADEQUATE DATA SOURCES TO FACILITATE INNOVATIVE PRICING SOLUTIONS FOR PHARMACEUTICALS WITH MULTIPLE INDICATIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PMU118 USE OF COMPUTER-ASSISTED METHODS TO REALIZE THE CONCEPT OF A LIVING SYSTEMATIC REVIEW VIA AN ONLINE PLATFORM

    Nov 1, 2019, 00:00

  • PCN333 PREFERENCE ELICITATION FOR CANCER TREATMENT IN EUROPE: A SYSTEMATIC LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS

    Nov 1, 2019, 00:00

  • PNS248 DOES THE EVALUATION OF THE FRENCH TRANSPARENCY COMMITTEE (TC) ON DRUG EFFECTIVENESS HAVE AN IMPACT ON THE HEALTH-ECONOMIC EVALUATION CONDUCTED BY THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)?

    Nov 1, 2019, 00:00

  • PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL

    Nov 1, 2019, 00:00

  • PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND

    Nov 1, 2019, 00:00

  • PMH49 PERSONALIZED HEALTHCARE EPISODE IDENTIFICATION IN SCHIZOPHRENIA SPECTRUM DISORDER USING HEALTHCARE CONSUMPTION TRAJECTORIES

    Nov 1, 2019, 00:00

  • PND73 FACTORS INFLUENCING INTENTION TO ENGAGE IN PREVENTIVE BEHAVIORS FOR ALZHEIMER'S DISEASE: A PROTECTION MOTIVATION THEORY APPROACH

    Nov 1, 2019, 00:00

  • PMH58 COMPARATIVE ANALYSIS BETWEEN THE MICROSTRUCTURE NETWORK MANAGEMENT AND THE CONVENTIONAL MEDICAL OF PERSONS WITH ADDICTION IN FRANCE

    Nov 1, 2019, 00:00

  • PNS70 THE EFFECT OF OUT-OF-POCKET HEALTHCARE PAYMENT ON THE FINANCES OF NIGERIAN FAMILIES

    Nov 1, 2019, 00:00

  • PCN40 A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS

    Nov 1, 2019, 00:00

  • PCN528 ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH LUNG CANCER AMONG A U.S. COHORT: A REAL WORLD APPROACH

    Nov 1, 2019, 00:00

  • PNS8 IDENTIFYING MECHANISMS IN PARTICIPANT RECRUITMENT IN THE DANSIH EQ-5D-5L VALUATION STUDY

    Nov 1, 2019, 00:00

  • PDG70 KNOWLEDGE, ATTITUDES AND PRACTICES OF MOROCCAN COMMUNITY PHARMACISTS TOWARDS THE THIRD-PARTY PAYER SYSTEM

    Nov 1, 2019, 00:00

  • PCN289 READINESS OF HEALTH SYSTEMS FOR THE INTRODUCTION OF TUMOUR-AGNOSTIC TREATMENT

    Nov 1, 2019, 00:00

  • PRO89 TOO ULTRA-RARE FOR CARE? ORPHAN DRUG AVAILABILITY FOR RESPIRATORY DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN363 IMPACT OF OUTCOMES ON IQWIGS OVERALL BENEFIT RATING

    Nov 1, 2019, 00:00

  • PNS409 ANALYSIS OF EPIDEMIOLOGY AND PHARMACOUTILIZATION ON PATIENTS AFFECTED BY OPHTHALMIC DISEASES WITH INDICATIONS FOR INTRAVITREAL TREATMENTS IN A NORTHERN ITALIAN REGION

    Nov 1, 2019, 00:00

  • PMS18 THE EXAMINATION AND DEVELOPMENT OF TRUNK STABILITY IN HIGH SCHOOL STUDENTS

    Nov 1, 2019, 00:00

  • PGI52 INTERNATIONAL ADAPTATION AND LINGUISTIC VALIDATION OF NASH-CHECK, A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • PNS294 REVIEW OF ANALYTICAL METHODS FOR ANALYSIS OF PATIENT REPORTED OUTCOME (PRO) DATA IN THE PRESENCE OF CENSORING DUE TO DEATH

    Nov 1, 2019, 00:00

  • PNS284 IS THERE A NEED FOR REAL WORLD EVIDENCE (RWE) IN HEALTH TECHNOLOGY ASSESSMENTS OF RARE DISEASES AND ONCOLOGY TREATMENTS?

    Nov 1, 2019, 00:00

  • PUK4 WHERE IS HYPERKALEMIA DIAGNOSED AND DOES IT MATTER? RESULTS FROM A LARGE EMR NETWORK IN THE US

    Nov 1, 2019, 00:00

  • PMU114 SPECIALISED HEALTH TECHNOLOGY ASSESSMENT PROCESSES FOR VERY RARE DISEASES: PAST, PRESENT AND FUTURE

    Nov 1, 2019, 00:00

  • PCN120 UTILIZATION AND EXPENDITURE OF COLORECTAL CANCER DRUGS IN THE MEDICAID PROGRAM FROM 1996 TO 2017

    Nov 1, 2019, 00:00

  • PMU19 RARE DISEASES AND THE COST FOR SOCIAL SECURITY SYSTEM: ESTIMATING THE SOCIO-ECONOMIC BURDEN IN ITALY

    Nov 1, 2019, 00:00

  • PMD7 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A BELGIAN HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN463 EUROQOL-5D ASSESSED HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS VS. GENERAL POPULATION IN BULGARIA

    Nov 1, 2019, 00:00

  • PRO57 COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • Multiple Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO159 PAEDIATRIC AND ADULT GHD TESTS FOR DIAGNOSIS IN EUROPE

    Nov 1, 2019, 00:00

  • PBI73 ASSESSMENT OF THE FUTURE IMPACT OF BIOSIMILARS AND GENERICS FOR ULCERATIVE COLITIS IN THE US EUROPE

    Nov 1, 2019, 00:00

  • PCN319 CONTEMPORARY EVIDENCE ON GLOBAL ECONOMIC BURDEN OF FRONTLINE CARE FOR PERIPHERAL T-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE

    Nov 1, 2019, 00:00

  • PCN504 REAL-WORLD PROGRESSION-FREE AND OVERALL SURVIVAL OF METASTATIC BREAST CANCER PATIENTS: ANALYSIS OF A NEW GERMAN EMR DATASET

    Nov 1, 2019, 00:00

  • PGI20 MULTIMATRIX VERSUS TIME-DEPENDENT DELIVERY OF MESALAZINE FOR ULCERATIVE COLITIS THERAPY IN KAZAKHSTAN: A HEALTH ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PCN133 A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF NEWLY DIAGNOSED MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIN7 ANALYSIS OF THE EFFECTIVENESS OF ENHANCE ADHERENCE COUNSELLING (EAC) ON VIRALLY UNSUPPRESSED HIV PATIENTS IN ST CHARLES BORROMEO HOSPITAL, ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA.

    Nov 1, 2019, 00:00

  • PGI60 IDENTIFYING PROGRESSING PATIENTS IN AN ARTIFICIAL INTELLIGENCE (AI) BASED COHORT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PNS17 ASSESSING TECHNOLOGIES THAT ARE EFFECTIVE BUT NOT COST-EFFECTIVE AT ZERO PRICE: AN ALTERNATIVE FRAMEWORK

    Nov 1, 2019, 00:00

  • PND110 SYMPTOM SEVERITY IN MULTIPLE SCLEROSIS FROM THE PATIENT'S PERSPECTIVE: REVISITING THE PSYCHOMETRIC PROPERTIES OF THE SYMPTOMSCREEN QUESTIONNAIRE (PERCEPTIONS-MS STUDY)

    Nov 1, 2019, 00:00

  • PCN83 COST-UTILITY ANALYIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PDG61 CANCER DRUGS SHORTAGES IN ROMANIA: MAGNITUDE, CAUSES AND SOLUTIONS

    Nov 1, 2019, 00:00

  • PCN262 ESTIMATION OF THE NUMBER OF PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN483 CONFIRMING THE PSYCHOMETRIC PERFORMANCE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–MELANOMA (FACT-M) QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA (MCC)

    Nov 1, 2019, 00:00

  • PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME

    Nov 1, 2019, 00:00

  • PGI7 THE CLINICAL IMPACT OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE ─ A CRITICAL LITERATURE REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PRO142 PSYCHOMETRIC PERFORMANCE OF THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)

    Nov 1, 2019, 00:00

  • PCN476 THE PATIENT JOURNEY WITH METASTATIC PROSTATE CANCER: A PILOT QUALITATIVE STUDY FROM GREECE

    Nov 1, 2019, 00:00

  • PDB27 ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS

    Nov 1, 2019, 00:00

  • PIH15 EXTERNAL VALIDATION OF THE EX-ANTE BUDGET IMPACT ANALYSIS FOR PALIVIZUMAB

    Nov 1, 2019, 00:00

  • PNS280 AN ASSESSMENT OF THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS WITHOUT A PATIENT ACCESS SCHEME OF COMMERCIAL ACCESS AGREEMENT

    Nov 1, 2019, 00:00

  • PNS241 EXPERIENCE AND IMPACT OF NICE SCIENTIFIC ADVICE: 10 YEARS ON

    Nov 1, 2019, 00:00

  • IN3 THE HEALTH SYSTEM BURDEN OF SELECTED VACCINE-PREVENTABLE ILLNESSES ON SECONDARY CARE IN ENGLAND: A FIVE-YEAR STUDY USING AN ADMINISTRATIVE HEALTHCARE DATASET

    Nov 1, 2019, 00:00

  • PCN156 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2019, 00:00

  • PNS413 DEVELOPMENT, VALIDATION AND CONCORDANCE OF CLINICAL CODE SETS USED IN REAL-WORLD DATABASE STUDIES

    Nov 1, 2019, 00:00

  • PCN188 THE COST-EFFECTIVENESS OF PARENTERAL NUTRITION IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PDG51 OPTIMIZING CHINA BMI FUNDS THROUGH DRUG VOLUME-BASED PROCUREMENT: UNDERSTANDING THE RESULT, IMPACT AND CHALLENGES

    Nov 1, 2019, 00:00

  • PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN389 MATURE VERSUS REGISTRATION STUDIES OF IMMUNO-ONCOLOGY AGENTS: DOES VALUE IMPROVE WITH TIME?

    Nov 1, 2019, 00:00

  • PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS

    Nov 1, 2019, 00:00

  • PNS238 THE CHANGING DYNAMICS OF PATIENT ACCESS SCHEMES IN ENGLAND

    Nov 1, 2019, 00:00

  • PDG43 ARE PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS AGREEMENTS ESSENTIAL FOR NICE TO RECOMMEND ACCESS? A COMPARISON OF ONCOLOGY AND NON-ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PIN9 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSU24 COMPARATIVE SAFETY OF SLEEVE GASTRECTOMY VS. ROUX-EN-Y: A RETROSPECTIVE COHORT ANALYSIS

    Nov 1, 2019, 00:00

  • PBI35 HEALTH ECONOMICS MODELLING FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): A TARGETED LITERATURE REVIEW (LR)

    Nov 1, 2019, 00:00

  • PNS245 SNAPSHOT OF EARLY ACCESS PROGRAMMES IN PORTUGAL: A NEW ACCESS HURDLE?

    Nov 1, 2019, 00:00

  • PND96 COMPARISON OF PROPENSITY SCORE METHODS A CASE STUDY OF DIRECT ORAL ANTICOAGULANTS

    Nov 1, 2019, 00:00

  • PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00

  • PCN295 THE BEHAVIOUR OF THE CANCER DRUGS FUND (CDF) OVER TIME; THE IMPACT OF INNOVATIVE THERAPIES AND IMPLICATIONS FOR MANAGED ENTRY AGREEMENTS

    Nov 1, 2019, 00:00

  • PIH59 KNOWLEDGE OF HUMAN PAPILLOMAVIRUSAMONG WOMEN LIVINGIN SOMOGY AND BARANYA COUNTIES, HUNGARY

    Nov 1, 2019, 00:00

  • PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PSY52 PATIENT-REPORTED OUTCOME MEASURES IN ATOPIC DERMATITIS AND CHRONIC HAND ECZEMA IN ADULTS

    Nov 1, 2019, 00:00

  • PIN32 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING ADULTS AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • PSY21 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMH4 ASSESSMENT OF QUALITY OF LIFE AMONGST PATIENTS DEPRESCRIBED WITH BENZODIAZEPINES

    Nov 1, 2019, 00:00

  • PNS60 CAN WE APPLY NICE COST-EFFECTIVENESS TO FRENCH EFFICIENCY OPTIONS: A COMPARISON OF SEVEN NICE AND HAS BASECASE COST-EFFECTIVENESS SCENARIOS

    Nov 1, 2019, 00:00

  • PDG30 PHARMACOECONOMIC EVALUATION OF ANTI-VEGF DRUGS AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIN97 ANTIMICROBIAL UTILIZATION AND INFECTION CAUSED BY GRAM-NEGATIVE BACTERIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN JAPAN: A MULTI-CENTRE CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PNS400 TREND IN STUDIES ON PATIENT REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PCN73 ECONOMIC EVALUATION OF TARGETED TREATMENTS FOR BRAFV600 POSITIVE MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PRS38 PREVALENCE OF SEVERE ASTHMA IN PORTUGAL: RESULTS FROM A PHYSICIANS SURVEY

    Nov 1, 2019, 00:00

  • PCV128 DEVELOPING AN EQ-5D-5L VALUE SET USING HEART DISEASE PATIENT'S PREFERENCES

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN28 METHOD TO ESTIMATE IMPACT OF PROGNOSTIC FACTORS ON SURVIVAL OUTCOMES USING MAXIMUM LIKELIHOOD ESTIMATION

    Nov 1, 2019, 00:00

  • PMS53 THE MOST COMMON REASONS FOR A MEDICAL VISIT AMONG PEOPLE PERFORMING CONDITIONING GYM WEIGHT TRAINING

    Nov 1, 2019, 00:00

  • PCN168 ECONOMIC BURDEN OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CLAIMS-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • PMU63 FRENCH HEALTH TECHNOLOGY ASSESSMENT OF DRUGS APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Nov 1, 2019, 00:00

  • PCN190 COST–BENEFIT ANALYSIS OF INTERVENTIONS MADE BY PHARMACISTS IN CHEMOTHERAPY PREPARATION OF A REFERRAL HOSPITAL IN IRAN

    Nov 1, 2019, 00:00

  • Medical Devices - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS383 HEALTH-RELATED QUALITY OF LIFE IN ROMANIA: CROSS-SECTIONAL STUDIES USING EQ-5D-3L AND EQ-5D-5L

    Nov 1, 2019, 00:00

  • PIN19 ECONOMIC EVALUATION OF THE FIRST PILOT OF PARTIAL DECENTRALIZATION OF HIV CARE AND TREATMENT FOR MEN WHO HAVE SEX WITH MEN IN GUATEMALA CITY FROM THE PATIENT'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • TP4 USE OF EPISODIC THERAPY IN MODERATE/SEVERE HEMOPHILIA A PATIENTS ACROSS THE EU5

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMU35 QUANTIFYING THE LOST MARKET SIZE OPPORTUNITY OF A TNF-INHIBITOR DUE TO DELAY IN TIME FROM PRIMARY TO SECONDARY INDICATION APPROVAL

    Nov 1, 2019, 00:00

  • PCN498 REAL-WORLD EVIDENCE ON THE UTILISATION OF ABIRATERONE AND ENZALUTAMIDE IN IRELAND

    Nov 1, 2019, 00:00

  • PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PND40 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Nov 1, 2019, 00:00

  • PRO43 BURDEN OF ILLNESS AMONG PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN300 CERVICAL CANCER PREVENTION IN INDONESIA: AN UPDATED CLINICAL IMPACT, COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PBI40 TENDER APPROACHES IN THE OFF-PATENT BIOLOGICAL MEDICINES MARKET: A EUROPEAN COMPARATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY?

    Nov 1, 2019, 00:00

  • PCN286 HEALTH TECHNOLOGY ASSESSMENT DECISIONS OVER THE LAST DECADE IN THE UNITED KINGDOM AND THE NETHERLANDS - A FOCUS ON NON-SMALL-CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PMD22 COST-EFFECTIVENESS ANALYSIS OF SUCROSE OCTASULFATE (URGOSTART) DRESSING IN THE TREATMENT OF DIABETIC FOOT AND VENOUS LEG ULCERS

    Nov 1, 2019, 00:00

  • PIH16 THE COST-EFFECTIVENESS OF STRATEGIES PREVENTING LATE-ONSET INFECTION IN PRETERM INFANTS

    Nov 1, 2019, 00:00

  • PRO81 EVOLVING COMMERCIALISATION OPPORTUNITIES IN RARE DISEASES OUTSIDE EUROPE

    Nov 1, 2019, 00:00

  • PBI52 ATMPS IN EUROPE: EXISTING CHALLENGES AND FUTURE DIRECTIONS

    Nov 1, 2019, 00:00

  • PDG13 CAN THE PURCHASING PERFORMANCE OF HEALTHCARE INSTITUTIONS BE ASSESSED VIA THE DATA DECLARED FOR REIMBURSEMENT?

    Nov 1, 2019, 00:00

  • PDB48 COST AND CAPACITY EFFECTS OF HEALTHYWEIGHTHUB @ VIRTUAL HOSPITAL 2.0 IN FINLAND

    Nov 1, 2019, 00:00

  • Copyright/Subscription

    Nov 1, 2019, 00:00

  • PNS300 HOW TO INTERPRET AND ACCOUNT FOR OVER/UNDER-DISPERSION WHEN MODELLING INCIDENCE RATES WITH POISSON MODELS

    Nov 1, 2019, 00:00

  • PUK19 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM FOR AUTOMATED PERITONEAL DYALISIS IN US

    Nov 1, 2019, 00:00

  • PND105 HEALTHCARE RESOURCE UTILIZATION OF MIGRAINE IN BRAZIL: RESULTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PCN523 INCIDENCE AND COST OF NON-CERVICAL HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PDG17 HOSPITAL COSTS ASSOCIATED WITH THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE IN HUNGARY

    Nov 1, 2019, 00:00

  • PNS287 PATIENT-CENTRICITY FOR PHARMACEUTICAL COMPANIES: NEW MODELS IN THE ERA OF CONNECTED HEALTH

    Nov 1, 2019, 00:00

  • PMS24 HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ELBOW AND FOREARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PRO33 IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PND113 DESIGN OF THE INDIVIDUALISED PARKINSON'S DEPENDENT QUALITY OF LIFE (PARKINSON'SDQOL) AND THE PARKINSONS TREATMENT SATISFACTION QUESTIONNAIRE (PARKINSON'STSQ) USING TEMPLATES AND ITEM LIBRARIES FROM EXISTING DQOL AND TSQ MEASURES FOR ...

    Nov 1, 2019, 00:00

  • PSY6 ABSENTEEISM IN ADULT PATIENTS WITH MODERATE-TO-SEVERE TREATED ATOPIC DERMATITIS IN PORTUGAL: AN ECONOMETRIC ANALYSIS

    Nov 1, 2019, 00:00

  • PCN215 COST COMPARISON OF LENALIDOMIDE BASED TRIPLE COMBINATION THERAPIES FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PND85 EFFICACY AND SAFETY OF ABOBOTULINUMTOXINA IN ADULTS WITH UPPER LIMB SPASTICITY AFTER STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIH48 EVALUATING COVERAGE EXPANSION FOR NON-INVASIVE PRENATAL TESTING THROUGH A PERFORMANCE-BASED RISK SHARING AGREEMENT

    Nov 1, 2019, 00:00

  • PDB30 THE INDIRECT COSTS OF DIABETES MELLITUS IN THE SLOVAK REPUBLIC

    Nov 1, 2019, 00:00

  • PBI76 EVOLUTION OF INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PRO60 PREVALENCE OF SANFILIPPO SYNDROME AND SUB-TYPES IN MAJOR GEOGRAPHICAL REGIONS

    Nov 1, 2019, 00:00

  • PCV68 ECONOMIC BURDEN OF ATHEROTROMBOTIC DISEASE IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PNS240 POTENTIAL INFLUENCE OF HTA ON PRICE OUTCOMES OF NON-ORPHAN PHARMACEUTICALS IN THE GERMAN AMNOG PROCESS

    Nov 1, 2019, 00:00

  • PDB51 PREVENTION AS A PUBLIC HEALTH MEASURE: LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF A POPULATION-BASED IODINE DEFICIENCY DISEASES PREVENTION PROGRAM

    Nov 1, 2019, 00:00

  • PNS180 MONITORING OF DRG-BASED PAYMENT FOR IN-PATIENT AND DAY CARE IN RUSSIAN HOSPITALS IN 2016-2018

    Nov 1, 2019, 00:00

  • PND34 ECONOMIC BURDEN OF PARKINSON'S DISEASE (PD) IN U.S.: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PRO37 HEALTHCARE RESOURCE USE IN CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY

    Nov 1, 2019, 00:00

  • PDG20 GLOBAL COMPARISON AND META-ANALYSIS OF INCREMENTAL COST-EFFECTIVENESS (ICER) FOR NEW CANCER DRUGS

    Nov 1, 2019, 00:00

  • PSY46 WORK PRODUCTIVITY LOSS IN PATIENTS WITH INFLAMMATORY ARTHRITIS

    Nov 1, 2019, 00:00

  • PDG57 DRUG PRICING PREDICTABILITY IN FRANCE: WHICH MANAGED ENTRY AGREEMENT SUITS THE BEST?

    Nov 1, 2019, 00:00

  • PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE

    Nov 1, 2019, 00:00

  • PCN134 SOCIO-ECONOMIC COSTS OF BREAST CANCER: AN ITALIAN ANALYSIS

    Nov 1, 2019, 00:00

  • PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE

    Nov 1, 2019, 00:00

  • PMD18 A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF C-REACTIVE PROTEIN POINT-OF-CARE TESTING TO GUIDE ANTIBIOTIC PRESCRIBING FOR RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE SETTINGS IN IRELAND

    Nov 1, 2019, 00:00

  • PBI87 REAL-WORLD GOLIMUMAB EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLARTHRITIS AND A TREATMENT FAILURE TO PREVIOUS TNFΑ INHIBITOR THERAPY

    Nov 1, 2019, 00:00

  • PSU38 COST-EFFECTIVE ANALYSIS OF THREE METHODS OF SURGICAL-SITE INFECTION SURVEILLANCE: LESS IS MORE

    Nov 1, 2019, 00:00

  • PNS188 ANALYSIS OF MARKET ACCESS AGREEMENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN271 HODGKIN LYMPHOMA IN EUROPEAN COUNTRIES: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMU93 ASSESSING THE OUTCOMES FOR ORPHAN STATUS OR ACCELERATED ASSESSMENT EMA APPROVED MEDICINES: A COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT IN DENMARK, FINLAND, NORWAY AND SWEDEN

    Nov 1, 2019, 00:00

  • PCV52 TRANSFERABILITY OF UK-BASED COST-EFFECTIVENESS MODEL TO HUNGARY, SWEDEN AND GERMANY: THE CASE OF MECHANICAL THROMBECTOMY BEYOND SIX HOURS FOLLOWING ADVANCED-IMAGING (VERSUS MECHANICAL THROMBECTOMY WITHIN SIX HOURS FOLLOWING CT+CTA) IN ...

    Nov 1, 2019, 00:00

  • PCV138 CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE PERIPHERAL ARTERY DISEASE QUALITY OF LIFE (PADQOL) QUESTIONNAIRE INTO HUNGARIAN: PILOTING RESULTS

    Nov 1, 2019, 00:00

  • PRO126 A COMPOSITE PROGNOSTIC SCORE FOR TIME TO LOSS OF WALKING ABILITY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00

  • PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE

    Nov 1, 2019, 00:00

  • PGI11 A BUDGET IMPACT MODEL FOR MEDICATION REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE PATIENTS TREATED WITH LAPAROSCOPIC NISSEN FUNDOPLICATION OR MAGNETIC SPHINCTER AUGMENTATION: AN ITALIAN PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIN26 ESTIMATING THE INVASIVE CANDIDIASIS COST-OF-CARE IN INTENSIVE CARE UNITS IN GREECE (HELICAS)

    Nov 1, 2019, 00:00

  • PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018

    Nov 1, 2019, 00:00

  • PIN16 COST-EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM + METRONIDAZOLE AS A FIRST-LINE TREATMENT IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS IN TAIWAN

    Nov 1, 2019, 00:00

  • PGI35 THE CLINICAL AND ECONOMIC IMPACT OF TDM (THERAPEUTIC DRUG MONITORING) ON CROHN DISEASE MANAGEMENT IN ITALY

    Nov 1, 2019, 00:00

  • PNS408 HOW IS THE ENGLISH NHS PRESCRIPTION DRUGS BUDGET SPENT

    Nov 1, 2019, 00:00

  • Mental Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PIN29 PUBLIC HEALTH AND ECONOMIC IMPACT OF VACCINATION OF SENIORS WITH A HIGH DOSE TRIVALENT INFLUENZA VACCINE IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM

    Nov 1, 2019, 00:00

  • PRO116 UNDERSTANDING THE ROLE OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENT FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PUK13 COST-EFFECTIVENESS OF INTRODUCING A DIETARY INTERVENTION FOR RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • RARE Public Health

    Nov 1, 2019, 00:00

  • PRS64 CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF LIFE QUESTIONNAIRE-BRONCHIECTASIS (QOL-B) IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NON-CF BE)

    Nov 1, 2019, 00:00

  • PNS22 USING TWITTER TO HARVEST DATA FROM SCIENTIFIC CONFERENCES:A PROOF OF CONCEPT OF A NEW APPROACH TO RETRIEVE CLINICAL TRIAL RESULTS

    Nov 1, 2019, 00:00

  • PDB103 HUMANISTIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN489 REAL WORLD MULTI-COUNTRY RETROSPECTIVE STUDY OF TREATMENT TRAVEL TIME AND WORK PRODUCTIVITY BURDEN AMONG HER2- NEGATIVE ADVANCED BREAST CANCER PATIENTS WITH A BRCA1/2 MUTATION

    Nov 1, 2019, 00:00

  • PCN493 PERCEPTIONS OF AND PARTICIPATION IN REAL-WORLD EVIDENCE RESEARCH AMONG US COMMUNITY ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PCN163 SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PMH5 PATIENTS MAY BE CONCERNED WITH THE CONSEQUENCES OF THEIR ANSWERS WHEN REPORTING ON SYMPTOMS OF DEPRESSION

    Nov 1, 2019, 00:00

  • PUK14 COST-EFFECTIVENESS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    Nov 1, 2019, 00:00

  • PRO77 INTERNATIONAL VARIATIONS IN THE APPRAISAL OF DRUGS FOR RARE DISEASES; WHAT ARE THE MAIN LESSONS?

    Nov 1, 2019, 00:00

  • PCN362 DO ANTICANCER DRUGS ENTERING THE FRENCH MARKET PROVIDE SIGNIFICANT EVIDENCE OF THEIR CLINICAL EFFICACY?

    Nov 1, 2019, 00:00

  • PCN420 NEW METHODOLOGIES IN PARAMETRIC NETWORK META-ANALYSIS: ACCOUNTING FOR POPULATION AGE DIFFERENCES BETWEEN TRIALS

    Nov 1, 2019, 00:00

  • PMD31 PERFORMANCE-BASED RISK SHARING AGREEMENTS: DO PAYERS CONSIDER MEDICINES AND MEDICAL DEVICES DIFFERENTLY?

    Nov 1, 2019, 00:00

  • PCV31 PATIENTS' PRODUCTIVITY LOSSES AND INFORMAL CARE COST RELATED TO ISCHEMIC STROKE IN RHONE AREA, FRANCE

    Nov 1, 2019, 00:00

  • PNS107 PHARMACISTS KNOWLEDGE OF PROJECT MANAGEMENT PROPOSAL OR CHART

    Nov 1, 2019, 00:00

  • PND100 REFINEMENT OF THE TREATMENT PREFERENCE QUESTIONNAIRE IN ADULTS WITH PARKINSON'S DISEASE AND OFF-EPISODES

    Nov 1, 2019, 00:00

  • PCN464 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF CANCER PATIENTS TREATED WITH IMMUNOTHERAPY: USE OF SOCIAL MEDIA IN FRENCH LANGUAGE TO EXPLORE RELEVANCE OF CONCEPTS COVERED BY CANCER GENERIC HRQOL MEASURES

    Nov 1, 2019, 00:00

  • PDB13 EVALUATING THE ECONOMIC AND HUMANISTIC BURDEN OF TYPE 2 DIABETES MELLITUS IN EMERGING MARKETS COMPARED TO ESTABLISHED MARKETS

    Nov 1, 2019, 00:00

  • PNS114 IMPROVING THE TRANSPARENCY OF MARKETING AUTHORISATION DECISIONS: TOWARDS A FRAMEWORK FOR MANAGING UNCERTAINTIES

    Nov 1, 2019, 00:00

  • PRO144 HEALTH-RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES MEASURES IN IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Drugs Information Systems

    Nov 1, 2019, 00:00

  • PBI34 BUDGET IMPACT OF TRASTUZUMAB BIOSIMILARS FOR THE TREATMENT OF BREAST CANCER AND GASTRIC CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PRO95 FROM DRUG ACCESS TO VALUE BASED HEALTHCARE: INTEGRATED CARE PATHWAYS FOR HEMOPHILIA IN ITALY

    Nov 1, 2019, 00:00

  • PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS66 NON-INFERIORITY TRIALS IN HEALTH TECHNOLOGY ASSESSMENT - DO THEY NECESSITATE A COST-MINIMISATION APPROACH?

    Nov 1, 2019, 00:00

  • PCV133 HETEROGENEITY IN PREFERENCES FOR ANTI-COAGULANT USE IN ATRIAL FIBRILLATION: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • PRO31 MEDICAL INNOVATION ASSESSMENT AND ECONOMIC BURDEN OF DISEASES ON THE EXAMPLE OF RARE AND COMMON DISEASES IN POLAND

    Nov 1, 2019, 00:00

  • PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PIN31 COST PER CYTOMEGALOVIRUS-ASSOCIATED DEATH AVERTED OF GANCICLOVIR AND VALGANCICLOVIR USE FOR PRE-EMPTIVE AND TREATMENT STRATEGIES IN ALLOGENEIC POSTTRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • PMU16 SOCIETAL DISEASE SEVERITY PREFERENCES WHEN VALUING AND PRIORITIZING HEALTHCARE INTERVENTIONS.

    Nov 1, 2019, 00:00

  • PNS54 FACIAL DRUG PRICES REGULATION BETWEEN 2011 AND 2018 IN FRANCE

    Nov 1, 2019, 00:00

  • PSU20 APPLY PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS IN MODEL FRAMEWORK DEVELOPMENT FOR SURGICAL DEVICE

    Nov 1, 2019, 00:00

  • PBI80 VARIATIONS IN TREATMENT PATTERNS OF PSORIASIS PATIENTS CURRENTLY EXPERIENCING 1ST LINE BIOLOGIC THERAPY IN EUROPE

    Nov 1, 2019, 00:00

  • PMH8 PSYCHOLOGICAL ASPECTS OF GENETIC COUNSELING IN RARE GENETIC CNS DISORDERS - SHOULD REGULATORS BE MORE INVOLVED?

    Nov 1, 2019, 00:00

  • PCV144 ANTITHROMBOTIC PRESCRIBING IN A SOUTH AFRICAN PRIVATE HEALTHCARE SETTING, WITH THE FOCUS ON RIVAROXABAN

    Nov 1, 2019, 00:00

  • PDG53 A FOCUS GROUP STUDY TO IDENTIFY THE FACTORS INFLUENCING PRIORITY SETTING IN HEALTHCARE: FOCUSING ON AGE AND SEVERITY

    Nov 1, 2019, 00:00

  • PCN274 CLINICAL FACTORS ASSOCIATED WITH ADHERENCE TO THE SECONDARY SCREENING FOR COLORECTAL CANCER ACCORDING TO AGE IN KOREAN NATIONAL CANCER SCREENING PROGRAM

    Nov 1, 2019, 00:00

  • PCN329 TREATMENT PATTERNS IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PATIENTS IN SPAIN.

    Nov 1, 2019, 00:00

  • PCN257 CERVICAL CANCER INCIDENCE IN A POPULATION OF 41,202 WOMEN SCREENED BY CONVENTIONAL CYTOLOGY AT A SINGLE PRIVATE LABORATORY OF SOUTHEAST BRAZIL

    Nov 1, 2019, 00:00

  • PCN392 UTILISATION OF REAL-WORLD EVIDENCE IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SUBMISSIONS OF THE TOP 20 ONCOLOGY DRUGS

    Nov 1, 2019, 00:00

  • PDG59 THE IMPACT OF TEMPORARY AUTHORIZATION USE (ATU) DOSSIER IN FRANCE SINCE THE CREATION OF FFIP (PHARMACEUTICAL INNOVATION FINANCING FUND) IN 2017

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCV62 ECONOMIC EVALUATION AND NETWORK META-ANALYSIS OF NON-STATIN THERAPY AMONG STATIN-TREATED PATIENTS IN THAILAND

    Nov 1, 2019, 00:00

  • PMU31 EARLY COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS MONITORING OF LUNG-AERATION WITH ELECTRICAL IMPEDANCE TOMOGRAPHY IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME

    Nov 1, 2019, 00:00

  • PNS128 READY FOR PRIME TIME? HAVE EMA PRIME DESIGNATIONS SUPPORTED ACCELERATED REGULATORY APPROVAL AND PATIENT ACCESS?

    Nov 1, 2019, 00:00

  • PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA

    Nov 1, 2019, 00:00

  • PMU67 PERFORMACE-BASED SCHEMES IN ITALY: IMPACT OF THEIR APPLICATION IN THE LAST 5 YEARS (2013-2017)

    Nov 1, 2019, 00:00

  • PMU21 COST-UTILITY ANALYSES OF INTERVENTIONS FOR INFORMAL CAREGIVERS: A SYSTEMATIC AND CRITICAL REVIEW

    Nov 1, 2019, 00:00

  • PNS271 TESTING OF A QUESTIONNAIRE FOR ASSESSMENT OF RELATIVE WEIGHTS OF MEDICINES VALUE CRITERIA

    Nov 1, 2019, 00:00

  • PCN74 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF-MUTATED METASTATIC MELANOMA PATIENTS IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • Alternative Medicine Information Systems

    Nov 1, 2019, 00:00

  • PNS82 HOW TO DEAL WITH CONTRADICTORY COST-EFFECTIVENESS OF THERAPEUTICALLY SIMILAR MEDICINES?

    Nov 1, 2019, 00:00

  • PCV113 MARKET ACCESS BARRIERS AND ADOPTION HURDLES FOR AI POWERED EHEALTH SOLUTIONS IN THE FIELD OF CARDIOLOGY

    Nov 1, 2019, 00:00

  • PSS12 COMPARATIVE ANALYSIS OF GLAUCOMA DRUG CONSUMPTION IN UKRAINE, ESTONIA, AND NORWAY

    Nov 1, 2019, 00:00

  • PMD2 IMPLANTABLE CARDIAC MONITORS (BIOMONITOR 2-AF, CONFIRM RX INSERTABLE CARDIAC MONITOR AND REVEAL LINQ INSERTABLE CARDIAC MONITORING SYSTEM) TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PMH50 THE LONGITUDINAL VALIDITY OF THE CHU9D - EVIDENCE FROM A MENTAL HEALTH TRIAL

    Nov 1, 2019, 00:00

  • Medical Devices - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCV148 ESTIMATE OF THE IMPACT AND COSTS OF CEREBROVASCULAR DISEASE FROM A HEALTH PLAN IN BRAZIL: REAL WORLD SCENARIO STUDY

    Nov 1, 2019, 00:00

  • PMS75 BURDEN OF DISEASE AND UNMET NEEDS OF KNEE OSTEOARTHRITIS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PND78 MULTIPLE SCLEROSIS IN PUERTO RICO: AN ANALYSIS OF DEMOGRAPHICS AND TREATMENT MODALITIES BY GEOGRAPHICAL REGION

    Nov 1, 2019, 00:00

  • PCN147 ENTRECTINIB IN NTRK TUMOR AGNOSTIC INDICATION COMPARED TO DIFFERENT STANDARD OF CARE IN VARIOUS TUMORS TYPES: A COST-EFFECTIVENESS ANALYSIS IN ITALIAN PATIENTS

    Nov 1, 2019, 00:00

  • PCN34 CLINICAL AND HUMANISTIC BURDEN AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PSY47 PATIENT-REPORTED OUTCOMES IN CHINESE ADULT RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN398 THE IMPORTANCE OF DIFFERENT ENDPOINTS IN ONCOLOGY-RELATED HEALTH TECHNOLOGY ASSESSMENTS: RESULTS OF A REVIEW OF DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PNS171 GEOGRAPHICAL INEQUALITIES OF GENERAL PRACTITIONER CARE IN HUNGARY BETWEEN 2009-2016

    Nov 1, 2019, 00:00

  • PCN431 EFFICACY PREDICTION IN PHASE I ONCOLOGY CLINICAL TRIALS USING DEEP LEARNING

    Nov 1, 2019, 00:00

  • PRO160 COST ESTIMATION OF IMMUNOGLOBULIN RESCUE IN HOSPITALIZED PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): ANALYSIS OF A BRAZILIAN PRIVATE HEALTHCARE SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PCN429 THE GENERATION OF SYNTHETIC CLINICAL TRIAL DATA

    Nov 1, 2019, 00:00

  • PRO48 COST OF HAEMATOPOIETIC STEM CELL TRANSPLANT IN TURKEY

    Nov 1, 2019, 00:00

  • PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO8 EFFICACY OF CFTR MODULATORS AGAINST PULMONARY EXACERBATION IN CYSTIC FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PMU133 TRANSLATION AND CULTURAL ADAPTATION OF 15D QUALITY OF LIFE QUESTIONNAIRE FROM ENGLISH TO ROMANIAN LANGUAGE

    Nov 1, 2019, 00:00

  • PCN3 RITUXIMAB-BASED REGIMEN AS FRONTLINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PMH26 MODEL DEVELOPMENT FOR ASSESSING COST-EFFECTIVENESS AND PREPARE REIMBURSEMENT DOSSIER OF RTMS IN PATIENT POPULATION WITH TREATMENT-RESISTANT DEPRESSION IN HUNGARY

    Nov 1, 2019, 00:00

  • PMS39 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE SHOULDER AND UPPER ARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS268 AGGREGATING MULTIPLE ENDPOINTS/PERFORMANCE INDICATORS TO CALCULATE A UNIDIMENSIONAL MEASUREMENT OF VALUE IN A COMPOSITE INDEX

    Nov 1, 2019, 00:00

  • PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PNS29 HEALTH RESEARCH AND BIG DATA IN UKRAINE: PERSPECTIVES AND CONCERNS

    Nov 1, 2019, 00:00

  • CE4 COMPARISON OF NETWORK META-ANALYSIS (NMA) USING THE BAYESIAN AND FREQUENTIST APPROACH: CONCRETE EXAMPLE ON THE BASIS OF A PUBLISHED NMA IN RELAPSING REMITTING MULTIPLE SCLEROSIS AND PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PCN502 RETROSPECTIVE GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] STUDY ON INITIAL TREATMENT OF BLADDER CARCINOMA (BCA) BY TRANSURETHRAL BLADDER RESECTION (TURB) - A COMPARATIVE ANALYSIS OF COSTS AND UROLOGICAL FOLLOW- ...

    Nov 1, 2019, 00:00

  • PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE

    Nov 1, 2019, 00:00

  • PNS265 MULTI-CRITERIA DECISION ANALYSIS AS A SUPPORTIVE TOOL FOR EFFICIENCY MEASURING IN HEALTH CARE

    Nov 1, 2019, 00:00

  • PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PMS54 FRACTURE LIAISON SERVICES

    Nov 1, 2019, 00:00

  • PCN403 IDENTIFYING KEY CRITERIA FOR HEALTH TECHNOLOGY ASSESSMENT FOR ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL: A MCDA APPROACH

    Nov 1, 2019, 00:00

  • PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS

    Nov 1, 2019, 00:00

  • Cost-Effectiveness Studies

    Nov 1, 2019, 00:00

  • PCV42 COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS

    Nov 1, 2019, 00:00

  • PDB4 A COST OFFSET ANALYSIS (COA) COMPARING REAL-TIME CONTINUOUS GLUCOSE MONITORING (RT-CGM) WITH INTERMITTENT SCANNING CONTINUOUS GLUCOSE MONITORING (IS-CGM) IN TYPE 1 DIABETES (T1D) SUBJECTS WITH IMPAIRED HYPOGLYCEMIA AWARENESS IN EIGHT C ...

    Nov 1, 2019, 00:00

  • PCN418 ASSESSMENT OF STUDIES EVALUATING INCREMENTAL COSTS, EFFECTIVENESS OR COST-EFFECTIVENESS OF SYSTEMIC THERAPIES IN BREAST CANCER BASED ON CLAIMS DATA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV33 COST-EFFECTIVENESS OF WEARABLE CARDIOVERTER-DEFIBRILLATOR IN CHINA: A DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PCN49 INDIRECT COMPARISON OF HRQOL DATA FOR PATIENTS WITH TREATMENT-REFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE REGORAFENIB (CORRECT TRIAL)

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCV82 ATHEROSCLEROSIS: BURDEN OF DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN479 PATIENT-REPORTED SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND26 ECONOMIC BURDEN OF HUNTINGTON'S DISEASE IN EUROPE

    Nov 1, 2019, 00:00

  • Neurological Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCV47 DOES THE COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN COMBINATION WITH STATIN THERAPY COMPARED TO STATIN ALONE DIFFER BETWEEN PRIMARY AND SECONDARY PREVENTION?

    Nov 1, 2019, 00:00

  • PBI86 INVESTIGATION ON THE CURRENT STATUS SURROUNDING BIOLOGICS AND THE IMPACT OF BIOSIMILARS USING JAPANESE REAL-WORLD DATA IN FY2017

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN505 COSTS AND TREATMENT PATHWAYS OF OVARIAN CANCER CARE IN KAZAKHSTAN: RETROSPECTIVE ANALYSIS OF PATIENT-LEVEL ELECTRONIC HEALTH RECORDS

    Nov 1, 2019, 00:00

  • Cardiovascular Diabetes Disorder Studies

    Nov 1, 2019, 00:00

  • PNS299 THE INCREASING USE AND ACCEPTANCE OF ALTERNATIVE STATISTICAL APPROACHES TO INDIRECT COMPARISON IN THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION PROCESS

    Nov 1, 2019, 00:00

  • PCN378 PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PCN375 WHEN EARLY MODELS MAY BE TOO EARLY - PREDICTING SURVIVAL FROM INTERIM ANALYSES

    Nov 1, 2019, 00:00

  • PNS395 PATIENT-REPORTED OUTCOME INSTRUMENTS IN ARABIC-SPEAKING POPULATIONS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS10 DEFINING CONFOUNDING BY INDICATION: RESOLVING THE GAP BETWEEN AN EPIDEMIOLOGIST AND ECONOMETRICIAN

    Nov 1, 2019, 00:00

  • PCN424 NETWORK META-ANALYSIS FOR IMMUNE ONCOLOGY TRIALS USING SPLINES

    Nov 1, 2019, 00:00

  • PMS22 ANNUAL COST OF PATIENTS UNDERGOING A TOTAL KNEE REPLACEMENT IN FRANCE

    Nov 1, 2019, 00:00

  • PBI43 THE IMPACT OF BIOSIMILAR PRICE CONTAGION ON NEW INNOVATION IN INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PNS167 QUANTITATIVE AND QUALITATIVE ANALYSIS OF DIFFERENCES IN AMNOG OUTCOMES BETWEEN IQWIG AND G-BA BETWEEN 2011-2018

    Nov 1, 2019, 00:00

  • PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?

    Nov 1, 2019, 00:00

  • PND108 QUALITY OF LIFE OF PATIENTS AFTER ISCHAEMIC STROKE TREATED IN A PROVINCIAL HOSPITAL IN POLAND

    Nov 1, 2019, 00:00

  • PCN508 A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA

    Nov 1, 2019, 00:00

  • PMU150 ISHLT REGISTRY DATA AND COUNTRY REGISTRIES: COMPARISON OF REPORTED COUNTRY LUNG TRANSPLANT ACTIVITIES IN NORTH AMERICA AND EUROPEAN COUNTRIES IN 2016

    Nov 1, 2019, 00:00

  • PCN280 CHARACTERIZING THE CONTINUED RELEVANCE OF IRP IN ITALY: A SIMULATION ANALYSIS OF TOP PRESCRIBED MOLECULES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • Infectious Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN302 NEW DRG-BASED REIMBURSEMENT OF RADIATION THERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • PCV32 COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA

    Nov 1, 2019, 00:00

  • PNS418 WHEN THE COMPARATOR HAS A CONFIDENTIAL PRICE - A REVIEW OF RECENT CASES IN SWEDEN

    Nov 1, 2019, 00:00

  • PNS96 TATTOO PREVALENCE, PERCEPTION AND REGRET IN US ADULTS: A 2017 CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • Individual's Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PNS207 CANCER-RELATED HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES BY EUROPEAN HTA AGENCIES: A COMPARATIVE ANALYSIS OF G-BA, HAS AND NICE

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN372 METHODOLOGIES FOR ADJUSTMENT OF THE TRIAL OVERALL SURVIVAL FOR TREATMENT SWITCHING: A REVIEW OF NICE SUBMISSIONS

    Nov 1, 2019, 00:00

  • PND23 HEALTHCARE EXPENDITURES ASSOCIATED WITH ADHERENCE TO ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • PDB25 COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

    Nov 1, 2019, 00:00

  • PRO136 PATIENT-REPORTED BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE USA AND UK MEASURED USING A DIGITAL APP

    Nov 1, 2019, 00:00

  • Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications

    Nov 1, 2019, 00:00

  • PSY14 A LITERATURE REVIEW TO IDENTIFY, CRITIQUE AND SELECT THE MOST SUITABLE ECONOMIC MODEL FOR USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) UK HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS

    Nov 1, 2019, 00:00

  • PRS27 THE USE OF ECONOMICAL TRADITIONAL HERBAL MEDICINAL PLANTS AMONG DIFFERENT COMMUNITIES OF BALOCHISTAN AGAINST ASTHMA

    Nov 1, 2019, 00:00

  • PDB81 HEALTHCARE RESOURCE USE ASSOCIATED WITH TYPE 2 DIABETES IN AFRICA, EURASIA, THE MIDDLE-EAST AND SOUTH-ASIA: RESULTS FROM THE 7TH WAVE OF THE INTERNATIONAL DIABETES MANAGEMENT PRACTICE STUDY (IDMPS)

    Nov 1, 2019, 00:00

  • PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER

    Nov 1, 2019, 00:00

  • PSY32 DELAY IN DIAGNOSIS OF PRIMARY LYMPHOEDEMA AND ITS IMPACT ON QUALITY OF LIFE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI71 EXPLORING UNCERTAINTIES AND SOLUTIONS ALLOWING PATIENT ACCESS TO CAR T-CELL THERAPIES: LEARNING TODAY HOW TO IMPROVE TOMORROW

    Nov 1, 2019, 00:00

  • ON3 HOSPITAL COSTS BEFORE, DURING, AND AFTER DIAGNOSIS OF FIVE CANCER FORMS IN DENMARK DURING 2014

    Nov 1, 2019, 00:00

  • PDG3 ANTI-VEGF DRUGS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION - A SYSTEMATIC REVIEW OF THE IMPACT OF ANTI-VEGF THERAPY ON REDUCING BLINDNESS AND VISUAL IMPAIRMENT

    Nov 1, 2019, 00:00

  • PCN21 TREATMENT COMPARISONS IN PATIENTS WITH UNRESECTABLE HEPTOCELLULAR CARCINOMA (HCC) WHO ARE INELIGIBLE FOR TRANSARTERIAL CHEMOEMBOLISATION (TACE)

    Nov 1, 2019, 00:00

  • PNS199 BARRIERS TO THE USE OF HEALTH SERVICES AMONG THE ELDERLY POPULATION OF A RURAL REGIONAL UNITY IN GREECE: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PNS372 A SIMULATION STUDY COMPARING THE PERFORMANCE OF DISCRETE CHOICE EXPERIMENT AND SWING WEIGHTING FOR ELICITATION OF PREFERENCES

    Nov 1, 2019, 00:00

  • PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PDB120 COSTS AND RESOURCE USE ASSOCIATED WITH SEVERE HYPOGLYCEMIC EVENTS IN PATIENTS WITH DIABETES IN IRAN

    Nov 1, 2019, 00:00

  • Clinical Outcomes Assessment Studies

    Nov 1, 2019, 00:00

  • PCN453 MODELING THE IMPACT OF NEXT GENERATION SEQUENCING BASED COMPREHENSIVE GENOMIC PROFILING PANEL ON TREATMENT PRACTICES IN ADVANCED OR METASTATIC CANCER

    Nov 1, 2019, 00:00

  • PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PDG85 TRUST THE EXPERTS? ACCEPTANCE OF EXPERT ELICITATION IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) SINGLE TECHNOLOGY APPRAISAL (STA) PROCESS

    Nov 1, 2019, 00:00

  • PNS369 RECOMMENDATIONS FOR CONDUCTING COGNITIVE INTERVIEWS REMOTELY TO DEVELOP CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PCN88 HOW ARE WE ASSESSING THE VALUE FOR MONEY OF CANCER BIOMARKERS IN ECONOMIC EVALUATIONS?

    Nov 1, 2019, 00:00

  • PNS255 USING PEST ANALYSIS TO CREATE AN HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • PNS32 AUTOMATIC ABSTRACT SCREENING USING MACHINE LEARNING TECHNIQUES: ARE WE THERE YET AND HOW CAN WE MOVE FORWARD?

    Nov 1, 2019, 00:00

  • PMU73 MONETIZATION OF ADDITIONAL BENEFIT OF ORPHAN DRUGS IN GERMAN ARBITRATION BOARD DECISIONS

    Nov 1, 2019, 00:00

  • Cancer - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMS34 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE WRIST AND HAND IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS122 LONG-ACTING GENE THERAPIES: CURRENT DEVELOPMENT ACTIVITIES AND CHALLENGES FOR GERMANY'S STATUTORY HEALTH INSURANCE SYSTEM

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44 (current)
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »